Illumina, Inc. $ILMN Stock Position Lifted by Keybank National Association OH

Keybank National Association OH grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.5% in the 3rd quarter, Holdings Channel reports. The fund owned 376,809 shares of the life sciences company’s stock after buying an additional 5,682 shares during the period. Keybank National Association OH’s holdings in Illumina were worth $103,125,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ILMN. Signature Equity Partners LLC boosted its stake in shares of Illumina by 246.5% in the 3rd quarter. Signature Equity Partners LLC now owns 149 shares of the life sciences company’s stock valued at $41,000 after purchasing an additional 106 shares in the last quarter. Fiduciary Financial Advisors bought a new stake in shares of Illumina during the 2nd quarter valued at approximately $26,000. MCF Advisors LLC grew its holdings in shares of Illumina by 172.4% during the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 100 shares during the last quarter. Keating Financial Advisory Services Inc. acquired a new position in Illumina during the 2nd quarter worth approximately $32,000. Finally, Rakuten Securities Inc. acquired a new position in Illumina during the 2nd quarter worth approximately $33,000. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on ILMN shares. Citigroup increased their price objective on shares of Illumina from $113.00 to $210.00 and gave the company a “sell” rating in a research note on Monday, November 2nd. Canaccord Genuity Group boosted their target price on shares of Illumina from $205.00 to $300.00 and gave the stock a “hold” rating in a research note on Monday, October 19th. Leerink Partners boosted their target price on shares of Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. Barclays upped their price target on shares of Illumina from $160.00 to $200.00 and gave the stock an “underweight” rating in a report on Wednesday, October 7th. Finally, JPMorgan Chase & Co. dropped their price target on Illumina from $320.00 to $300.00 and set an “overweight” rating for the company in a research note on Friday, October 30th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $244.24.

Illumina Stock Down 2.7%

Shares of NASDAQ ILMN opened at $214.91 on Wednesday. The company has a market capitalization of $32.49 billion, a P/E ratio of 42.05, a price-to-earnings-growth ratio of 3.00 and a beta of 1.46. Illumina, Inc. has a 52-week low of $112.65 and a 52-week high of $309.35. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63. The company’s 50 day moving average price is $249.27 and its 200-day moving average price is $178.77.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, beating analysts’ consensus estimates of $1.36 by $0.26. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same period in the prior year, the firm posted $1.34 EPS. The company’s quarterly revenue was up 4.2% on a year-over-year basis. Equities analysts forecast that Illumina, Inc. will post 5.43 earnings per share for the current year.

Insider Transactions at Illumina

In other Illumina news, Director Keith Meister sold 299,336 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the sale, the director owned 1,409,851 shares of the company’s stock, valued at approximately $307,291,123.96. This represents a 17.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 1,601,541 shares of company stock valued at $354,755,291 in the last quarter. 2.90% of the stock is owned by insiders.

About Illumina

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.